159 related articles for article (PubMed ID: 38263580)
21. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
Jonker D; Rumble RB; Maroun J;
Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
[TBL] [Abstract][Full Text] [Related]
22. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K;
Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101
[TBL] [Abstract][Full Text] [Related]
23. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
[TBL] [Abstract][Full Text] [Related]
24. [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].
Schneider R; Schneider C; Büttner R; Reinacher-Schick A; Tannapfel A; Fürst A; Rüschoff J; Jakobeit C; Royer-Pokora B; Möslein G
Zentralbl Chir; 2015 Dec; 140(6):591-9. PubMed ID: 25372301
[TBL] [Abstract][Full Text] [Related]
25. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation.
Chung C
J Oncol Pharm Pract; 2022 Jun; 28(4):850-869. PubMed ID: 33832365
[TBL] [Abstract][Full Text] [Related]
26. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
27. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
28. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
29. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
30. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH
Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309
[TBL] [Abstract][Full Text] [Related]
31. Real-world first-line treatment of patients with BRAF
Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
[TBL] [Abstract][Full Text] [Related]
32. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
33. BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.
Kasi PM; Kamatham S; Shahjehan F; Li Z; Johnson PW; Merchea A; Colibaseanu DT
J Gastrointest Oncol; 2020 Apr; 11(2):236-241. PubMed ID: 32399264
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
35. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
36. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
37. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
39. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.
Ricker CN; Hanna DL; Peng C; Nguyen NT; Stern MC; Schmit SL; Idos GE; Patel R; Tsai S; Ramirez V; Lin S; Shamasunadara V; Barzi A; Lenz HJ; Figueiredo JC
Cancer; 2017 Oct; 123(19):3732-3743. PubMed ID: 28640387
[TBL] [Abstract][Full Text] [Related]
40. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]